Shining a light on soligenix's hybryte(tm) growth opportunity

Company connecting the dots for final fda approvalnew york, new york--(newsfile corp. - june 3, 2021) - pcg digital -- when soligenix (nasdaq: sngx) updated its nda rollout plan, the market quickly reacted. while the timeline was adjusted, the big picture and ultimate end game remain the same. with conditional acceptance of the hybrytetm name by the fda and positive news in japan and the uk, soligenix continues to move forward in its aim to treat cutaneous t cell lymphoma.soligenix is developing...
SNGX Ratings Summary
SNGX Quant Ranking